CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 37 enrolled
Drug / intervention
TAK-085drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02824432
NCT02824432Phase 4Completed
CompareCT.gov

Exploratory Study of the Effect of Omega-3-acid Ethyl Esters on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation

Takeda·interventional·Posted Jul 6, 2016·Updated May 6, 2019

In Brief

A Phase 4 clinical trial evaluating TAK-085 for Hyperlipidemia. Completed, enrolled 37 participants across 4 sites.

Detailed Summary

The purpose of this study is to explore the effects of omega-3-acid ethyl esters (TAK-085) on vascular endothelial function when administered for 8 weeks, as measured by FMD, in patients with hyperlipidemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperlipidemia
CountriesJapan
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 6, 2016
Enrollment StartAug 4, 2016
Primary CompletionAug 19, 2017
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 10.0 years ago

Interventions

TAK-085drug

TAK-085 capsules